Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.38 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.38 |
| ▸ | DHFR | P00374 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3441092 | 0.83 | TLR7 (0.43) | TLR7KDM4EALDH1A1NPSR1HSD17B10 | |
| SCHEMBL3441007 | 0.82 | FBP1 (0.50) | TLR7KDM4EALDH1A1NPSR1HSD17B10 | |
| SCHEMBL3441078 | 0.80 | MEN1 (0.46) | TLR7KDM4EALDH1A1NPSR1HSD17B10 | |
| SCHEMBL3441222 | 0.80 | ALDH1A1 (0.46) | TLR7KDM4EALDH1A1NPSR1HSD17B10 | |
| SCHEMBL3441043 | 0.78 | HSP90AA1 (0.50) | TLR7ALDH1A1HSP90AA1HSP90AB1ERBB2 | |
| SCHEMBL3441040 | 0.78 | TLR7 (0.39) | TLR7KDM4EALDH1A1NPSR1HSD17B10 | |
| SCHEMBL3441083 | 0.77 | RXFP1 (0.45) | TLR7KDM4EALDH1A1NPSR1HSD17B10 | |
| SCHEMBL3441218 | 0.77 | HSP90AA1 (0.49) | TLR7ALDH1A1HSP90AA1HSP90AB1ERBB2 | |
| SCHEMBL3441183 | 0.76 | TLR7 (0.47) | TLR7KDM4EALDH1A1NPSR1HSD17B10 | |
| SCHEMBL3441461 | 0.75 | CYP2D6 (0.43) | TLR7ALDH1A1MEN1KMT2AHSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2200615-A1 | A3 ADENOSINE RECEPTOR ANTAGONISTS | Gilead Palo Alto, Inc. (US) | 2010-06-30 | — | — | EP | disclosed |
| WO-2009052310-A1 | A3 ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC (US) | 2009-04-23 | — | — | WO | disclosed |
| US-20090099212-A1 | A3 ADENOSINE RECEPTOR ANTAGONISTS | ZABLOCKI JEFF | 2009-04-16 | — | — | US | disclosed |
| US-7238700-B2 | A2B adenosine receptor antagonists | CV THERAPEUTICS, INC. (US) | 2007-07-03 | — | — | US | disclosed |
| EP-1401837-B1 | PURINE DERIVATIVES AS A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS INC (US) | 2005-10-19 | — | — | EP | disclosed |
| US-20040209899-A1 | A2B adenosine receptor antagonists | PALLE VENKATA (IN) | 2004-10-21 | — | — | US | disclosed |
| US-6770651-B2 | THERAPY FOR ASTHMA, DIARRHEA | PALLE VENKATA (US) | 2004-08-03 | — | — | US | disclosed |
| EP-1401837-A1 | PURINE DERIVATIVES AS A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2004-03-31 | — | — | EP | disclosed |
| US-20030064999-A1 | A2B adenosine receptor antagonists | PALLE VENKATA (US) | 2003-04-03 | — | — | US | disclosed |
| WO-2003006465-A1 | PARTIAL AND FULL AGONIST OF A ADENOSINE RECEPTORS | CV THERAPEUTICS, INC. (US) | 2003-01-23 | — | — | WO | disclosed |
| WO-2003002566-A1 | PURINE DERIVATIVES AS A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2003-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030064999-A1 | A2B adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA1 | TLR7 1635/4885KDM4E 4142/4885ALDH1A1 734/4885 |
| US-20090099212-A1 | A3 ADENOSINE RECEPTOR ANTAGONISTS | ADORA3, ADORA2A, ADORA2B | TLR7 2170/4885KDM4E 4348/4885ALDH1A1 831/4885 |
| US-20040209899-A1 | A2B adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA1 | TLR7 854/4885KDM4E 2409/4885ALDH1A1 520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.